Vivo Bio Tech Ratios

Vivo Bio Tech Ltd Ratios

The Vivo Bio Tech Ltd Ratios page provides a complete fundamental analysis of Vivo Bio Tech Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Vivo Bio Tech Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Vivo Bio Tech Ltd (NSE: , BSE: 511509) is currently trading at ₹27.03, with a market capitalization of ₹599.81M. As a major player in the Distribution services sector and Medical distributors industry, Vivo Bio Tech Ltd remains a key stock for fundamental analysis using Vivo Bio Tech Ltd Ratios.

Vivo Bio Tech Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Vivo Bio Tech Ltd P/E ratio currently stands at 7.13, making it one of the most tracked metrics in Vivo Bio Tech Ltd Ratios.

Historically, the Vivo Bio Tech Ltd P/E ratio has shown strong fluctuations:

• 2024: 7.13
• 2023: 28.31
• 2022: 10.80
• 2021: 25.51
• 2020: 11.33

The decline in Vivo Bio Tech Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Vivo Bio Tech Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.75.

Historical P/B trend:

• 2024: 0.75
• 2023: 1.17
• 2022: 0.55
• 2021: 1.20

Vivo Bio Tech Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Vivo Bio Tech Ltd P/S ratio currently stands at 1.11, an important part of Vivo Bio Tech Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.11
• 2023: 1.57
• 2022: 0.55
• 2021: 1.09

A stable or declining Vivo Bio Tech Ltd P/S ratio indicates cautious market sentiment.

Vivo Bio Tech Ltd Price to Cash Flow Ratio (P/CF)

The Vivo Bio Tech Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 8.17.

Historical Vivo Bio Tech Ltd Price to Cash Flow Ratio:

• 2024: 8.17
• 2023: 7.71
• 2022: 3.35
• 2021: 4.06
• 2020: 4.54

The rising Vivo Bio Tech Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Vivo Bio Tech Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Vivo Bio Tech Ltd EV currently stands at ₹1.05B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 1.05B
• 2023: 1.43B
• 2022: 896.31M
• 2021: 1.22B

Vivo Bio Tech Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Vivo Bio Tech Ltd EV/EBITDA ratio is currently 5.09, a key metric in Vivo Bio Tech Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 5.09
• 2023: 6.73
• 2022: 4.10
• 2021: 7.53

Stable Vivo Bio Tech Ltd EV/EBITDA indicates balanced valuation.

Vivo Bio Tech Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Vivo Bio Tech Ltd D/E ratio is currently 0.69, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.69
• 2023: 1.34
• 2022: 1.20
• 2021: 1.43

Vivo Bio Tech Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Vivo Bio Tech Ltd ROE currently stands at 11.01%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.01
• 2023: 4.75
• 2022: 5.35
• 2021: 4.91

Vivo Bio Tech Ltd maintains stable profitability levels.

Vivo Bio Tech Ltd Ratios Analysis Summary

The Vivo Bio Tech Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Vivo Bio Tech Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Vivo Bio Tech Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.